Semaglutide denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Semaglutide as Duplicate Therapy — and How to Appeal

A duplicate-therapy denial from Blue Cross Blue Shield means the plan's system flagged that you are already receiving another medication it considers therapeutically equivalent to semaglutide. This is often a technical or administrative error — the medications may share a broad class but differ clinically in mechanism, formulation, indication, or tolerability profile. These denials are frequently overturned on appeal.

## Why This Denial Happens

BCBS plans use drug utilization review (DUR) edits that trigger when two agents from the same therapeutic category are billed simultaneously. Semaglutide may share a broad classification with another agent on your profile, but that classification does not mean the two drugs are interchangeable for your specific clinical situation. The prescriber's judgment about which agent is appropriate for you is a key fact the plan must weigh on appeal.

## Your Federal Appeal Rights

• Internal appeal: You typically have 180 days from the denial notice to file. BCBS must decide standard appeals within 30–60 days and urgent appeals within 72 hours.
• External review (ACA §2719): If the internal appeal is denied, request independent external review within approximately 4 months of the final internal decision. An Independent Review Organization applies clinical standards, not BCBS's formulary edits.
• ERISA §503: For employer self-funded plans, full-and-fair review applies, and federal court review is a backstop.
• Expedited option: Request expedited processing if delay would seriously harm your health.

## Documentation to Gather

1. Diagnosis specificity: Chart notes confirming the exact indication for semaglutide and whether it differs from the indication for the other agent flagged as a duplicate. 2. Clinical differentiation letter: A letter from your prescriber explaining why the two agents are not therapeutically interchangeable for you — addressing mechanism of action, formulation differences, prior response, tolerability, or indication-specific evidence as documented in the FDA-approved prescribing information for each drug. 3. Medication list with dates: A complete, dated medication list showing when the other agent was started, its current status, and whether it is actually being used concurrently or has been discontinued. 4. BCBS's duplicate-therapy policy: Request the specific DUR edit criteria from BCBS member services so your appeal can address each criterion by name.

## Criteria-Mapping Structure

For each reason BCBS cites as the basis for the duplicate flag, provide a direct response:

| BCBS Duplicate-Therapy Criterion | Your Clinical Response | |---|---| | [Therapeutic class overlap cited] | [Prescriber explanation of clinical distinction] | | [Concurrent use prohibition language] | [Medication list showing actual use status with dates] | | [Any formulary preference criterion] | [Chart evidence why preferred agent is inappropriate] |

Organize all exhibits with a numbered index and attach the prescriber's letter as Exhibit A. The cover letter should state the denial date, identify the specific DUR edit by name if known, and request that a physician reviewer — not only a pharmacy reviewer — evaluate the appeal.